| Previous Close | 142.56 |
| Open | 142.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 141.75 - 142.90 |
| 52 Week Range | 120.75 - 150.28 |
| Volume | 91,533 |
| Avg. Volume | 110,047 |
| Net Assets | 19.53B |
| NAV | 147.72 |
| PE Ratio (TTM) | N/A |
| Yield | 1.00% |
| YTD Return | 11.38% |
| Beta (3y) | 1.08 |
| Expense Ratio (net) | 0.07% |
| Inception Date | 2004-01-26 |
- Market Realist•23 days ago
Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).
- Market Realist•26 days ago
Understanding Abiomed’s Changing Payment Structure Plans for Impella
Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.
- Motley Fool•2 months ago
Best Growth ETFs for 2017 and Beyond
Growth stock ETFs can allow you to profit from rapidly-growing companies while diversifying your risk.
